Calidi Biotherapeutics Announces Director Changes and Agreements
Ticker: CLDWW · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $85,000, $212,500, $250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, material-agreement
TL;DR
Calidi Biotherapeutics swapped a director and signed a new deal. Board changes + new agreement = watch this space.
AI Summary
Calidi Biotherapeutics, Inc. announced on August 8, 2025, the departure of Director Dr. Jonathan R. Roth and the appointment of Dr. Michael J. Ybarra as a new director. The company also entered into a material definitive agreement and disclosed compensatory arrangements for certain officers. This filing follows their previous name change from First Light Acquisition Group, Inc. on April 6, 2021.
Why It Matters
Changes in board composition and material agreements can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director departures and new appointments, alongside material agreements, can introduce uncertainty or indicate strategic shifts that may affect the company's risk profile.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- Dr. Jonathan R. Roth (person) — Departing Director
- Dr. Michael J. Ybarra (person) — Appointed Director
- First Light Acquisition Group, Inc. (company) — Former Company Name
- August 8, 2025 (date) — Date of earliest event reported
- April 6, 2021 (date) — Date of name change
FAQ
Who has been appointed as a new director to Calidi Biotherapeutics, Inc.'s board?
Dr. Michael J. Ybarra has been appointed as a new director.
Who has departed from the board of directors at Calidi Biotherapeutics, Inc.?
Dr. Jonathan R. Roth has departed from the board of directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 8, 2025.
What was Calidi Biotherapeutics, Inc.'s former company name?
Calidi Biotherapeutics, Inc.'s former company name was First Light Acquisition Group, Inc.
When did the company change its name from First Light Acquisition Group, Inc.?
The company changed its name on April 6, 2021.
Filing Stats: 992 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-09-19 17:00:14
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $85,000 — ated to pay i) a bonus in the amount of $85,000, upon the successful and effective corp
- $212,500 — ell prior to October 31, 2025, and (ii) $212,500 severance pay in the form of compensati
- $250 — ent, Ms. Campbell will be paid a fee of $250 per hour (for a maximum of 20 hours per
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 57KB
- ex10-2.htm (EX-10.2) — 57KB
- ex10-2_001.jpg (GRAPHIC) — 15KB
- 0001493152-25-014293.txt ( ) — 367KB
- cldi-20250808.xsd (EX-101.SCH) — 3KB
- cldi-20250808_lab.xml (EX-101.LAB) — 33KB
- cldi-20250808_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: September 19, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer